NASDAQ:CARA
Cara Therapeutics Stock News
$0.716
-0.0445 (-5.85%)
At Close: May 10, 2024
Cara Therapeutics Inc (NASDAQ:CARA) SVP Frederique Ph.D. Menzaghi Sells 12,894 Shares of Stock
09:22am, Wednesday, 22'nd Apr 2020
Cara Therapeutics Inc (NASDAQ:CARA) SVP Frederique Ph.D. Menzaghi sold 12,894 shares of the firm’s stock in a transaction dated Tuesday, April 21st. The stock was sold at an average price of $15.58,
Cara Therapeutics (NASDAQ:CARA) Now Covered by Needham & Company LLC
07:40am, Wednesday, 22'nd Apr 2020
Needham & Company LLC assumed coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research report issued to clients and investors on Tuesday, TipRanks reports. The brokerage set a “buy” rat
Short Interest in Cara Therapeutics Inc (NASDAQ:CARA) Declines By 13.2%
06:58am, Wednesday, 22'nd Apr 2020
Cara Therapeutics Inc (NASDAQ:CARA) was the target of a large decline in short interest in the month of March. As of March 31st, there was short interest totalling 3,690,000 shares, a decline of 13.2%
Cannabis Stock Gainers And Losers From April 21, 2020
01:04am, Wednesday, 22'nd Apr 2020
Gainers
Body and Mind (OTC: BMMJ) shares closed up 23.61% at $0.38
Cann Group (OTC: CNGGF) shares closed up 12.5% at $0.54
AusCann Group Holdings (OTC: ACNNF)...
Cara Therapeutics Itching Drug Scratches Off Goals of Phase 3 Test
08:52pm, Tuesday, 21'st Apr 2020
A Cara Therapeutics drug developed to treat the severe itching experienced by patients receiving hemodialysis has met the main goal of a second late-stage
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright CARA
04:07pm, Tuesday, 21'st Apr 2020
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright H.C. Wainwright CARA
Cara Therapeutics (CARA) Receives a Buy from Needham
03:58pm, Tuesday, 21'st Apr 2020
In a report released today, Alan Carr from Needham assigned a Buy rating to Cara Therapeutics (CARA), with a price target of $35.00. The company's shares
Cara Therapeutics (CARA) Receives a Buy from Needham
03:58pm, Tuesday, 21'st Apr 2020
In a report released today, Alan Carr from Needham assigned a Buy rating to Cara Therapeutics (CARA – Research Report),
Cara Therapeutics (CARA) Gets a Buy Rating from H.C. Wainwright
03:43pm, Tuesday, 21'st Apr 2020
H.C. Wainwright analyst Oren Livnat maintained a Buy rating on Cara Therapeutics (CARA) today and set a price target of $33.00. The company's shares
Cara Therapeutics (CARA) Gets a Buy Rating from H.C. Wainwright
03:43pm, Tuesday, 21'st Apr 2020
H.C. Wainwright analyst Oren Livnat maintained a Buy rating on Cara Therapeutics (CARA – Research Report) today and set a
The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives
12:19pm, Tuesday, 21'st Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 20) * Abbott Laboratories (NYSE: ABT) * Acceleron Phar
Cara Therapeutics' Shares March Higher, Can It Continue?
12:07pm, Tuesday, 21'st Apr 2020
As of late, it has definitely been a great time to be an investor in Cara Therapeutics.
Cara Therapeutics' Shares March Higher, Can It Continue?
12:07pm, Tuesday, 21'st Apr 2020
As of late, it has definitely been a great time to be an investor in Cara Therapeutics.
Cara's Korsuva successful in second late-stage study
10:38am, Tuesday, 21'st Apr 2020
Cara Therapeutics (NASDAQ:CARA) and licensee Vifor Fresenius Medical Care Renal Pharma announce positive results from a Phase 3 clinical trial, KALM-2, evaluating Korsuva (CR845/difelikefalin) Injecti
Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.02) Statisticall…
